@article{fbf1278888db4eacaf048d3d42335b56,
title = "DNA patents and diagnostics: Not a pretty picture",
author = "Julia Carbone and Gold, {E. Richard} and Bhaven Sampat and Subhashini Chandrasekharan and Lori Knowles and Misha Angrist and Robert Cook-Deegan",
note = "Funding Information: In the case of Myriad, initial research took place at the University of Utah—with public funding from the US National Institutes of Health (NIH; Bethesda, MD, USA). The researchers then spun off Myriad, which attracted investment from Eli Lilly (Indianapolis, IN, USA) and succeeded in patenting BRCA1 and a diagnostic test for breast cancer (patents that were ultimately jointly assigned to the University of Utah, Myriad and the NIH). Rather than licensing out the test to clinical geneticists and laboratories around the world, Myriad required initial testing in each family to be performed at its laboratories in Salt Lake City. In the United States, the company sent out cease-and-desist letters to laboratories—both academic and commercial—already performing tests when the patent was issued.",
year = "2010",
month = aug,
doi = "10.1038/nbt0810-784",
language = "English (US)",
volume = "28",
pages = "784--791",
journal = "Biotechnology",
issn = "1087-0156",
publisher = "Nature Publishing Group",
number = "8",
}